Multiple Myeloma;minimal residual disease;ODAC;FDA;C. Ola Landgren;Sylvester Multiple Myeloma Institute;Sylvester Myeloma Institute;Oncologic Drugs Advisory Committee
-
Health News
FDA’s ODAC Rules Unanimously on a Faster Way to Approve Multiple Myeloma Therapies
[ad_1] Newswise — MIAMI, FLORIDA (April 12, 2024) – An advisory committee at the U.S. Food and Drug Administration voted…
Read More »